Time-restricted Eating and Interval Training With Digital Follow-up
NCT ID: NCT05505305
Last Updated: 2024-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2022-09-01
2024-05-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Time Restricted Eating in Obese Adults
NCT05660291
Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity
NCT02480504
Exercise and Weight Control
NCT02152501
Chronic Effect of Fasting
NCT03574103
Time-restricted Eating Acceptability, Efficacy and Safety in Obesity
NCT06695988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Time-restricted eating and high-intensity interval training
Seven weeks of time-restricted eating and high-intensity interval training with digital follow-up.
Time-restricted eating and high-intensity interval training
Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
Control
No intervention nor digital follow-up for seven weeks.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Time-restricted eating and high-intensity interval training
Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to walk or ride a bike \> 60 min
Exclusion Criteria
* Lactation within 24 weeks of study commencement
* High-intensity exercise ≥ 1/week
* Habitual eating window ≤12 hours/day
* Taking hypertension, glucose-, or lipid-lowering drugs
* Body mass variation ≥ 4 kg three months prior to study commencement
* Known diabetes mellitus (type 1 or 2) or cardiovascular disease
* Working night shifts
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Norwegian University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Øivind Rognmo, PhD
Role: STUDY_DIRECTOR
Norwegian University of Science and Technology, Trondheim, Norway
Trine Moholdt, PhD
Role: PRINCIPAL_INVESTIGATOR
Norwegian University of Science and Technology, Trondheim, Norway
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of circulation and medical imaging, NTNU
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
479143
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.